Table 4.
Outcomes of patients in first (CR1) versus a later complete remission (CR ≥ 2) versus those not in CR
| Autologous | Allogeneic | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR1 | CR ≥2 | Non-CR | CR1 | CR ≥2 | Non-CR | ||||||||
| Outcome event |
N | Prob (95% CI) |
N | Prob (95% CI) |
N | Prob (95% CI) |
N | Prob (95% CI) |
N | Prob (95% CI) |
N | Prob (95% CI) |
P-valuea |
| Progression/ | 48 | 19 | 38 | 30 | 39 | 41 | |||||||
| Relapse | |||||||||||||
| @ 1 year | 13 (5–24) | 44 (21–65) | 55 (38–69) | 24 (10–39) | 49 (32–63) | 54 (37–67) | <0.001 | ||||||
| @ 5 years | 18 (8–30) | 50 (26–70) | 67 (49–79) | 27 (13–44) | 49 (32–63) | 54 (37–67) | <0.001 | ||||||
| PFS | 48 | 19 | 38 | 30 | 39 | 41 | |||||||
| @ 1 year | 85 (71–93) | 50 (26–70) | 34 (20–49) | 53 (34–69) | 30 (17–45) | 14 (6–27) | <0.001 | ||||||
| @ 5 years | 78 (63–88) | 44 (21–65) | 19 (9–34) | 50 (30–66) | 27 (15–42) | 11 (4–24) | <0.001 | ||||||
| Overall | |||||||||||||
| survival | 48 | 19 | 38 | 30 | 39 | 42 | |||||||
| @ 1 year | 85 (72–93) | 53 (29–72) | 37 (22–52) | 53 (34–69) | 31 (17–45) | 16 (6–28) | <0.001 | ||||||
| @ 5 years | 83 (69–91) | 53 (29–72) | 22 (10–36) | 53 (34–69) | 28 (15–43) | 12 (4–25) | <0.001 | ||||||
Abbreviations TRM = treatment-related mortality; PFS = progression-free survival; PROB = probability; CI = confidence interval.
a
Probabilities of treatment-related mortality and progression/relapse were calculated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimate.